Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Amit Sanyal, MD: A Clinician’s Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Sep
23
Today In Oncology
ASCO Breakthrough Studies Target Supportive Care Problems That Can Derail Treatment
Dual Oral Regimen Shows Encouraging Activity in KRAS G12C–Mutated Metastatic Colorectal Cancer
BRAF Class Alterations in NSCLC Have Different Characteristics, Outcomes, and Co-Mutations, Research Shows
AACR Releases Annual Cancer Progress Report
Plant-Based Diet Linked to Lower Risk of Prostate Cancer Progression on Active Surveillance
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo